Growth Metrics

Novavax (NVAX) Capital Leases (2020 - 2025)

Historic Capital Leases for Novavax (NVAX) over the last 9 years, with Q3 2025 value amounting to $2.3 million.

  • Novavax's Capital Leases fell 9582.66% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 9582.66%. This contributed to the annual value of $53.7 million for FY2024, which is 392.86% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Capital Leases is $2.3 million, which was down 9582.66% from $52.4 million recorded in Q2 2025.
  • Over the past 5 years, Novavax's Capital Leases peaked at $55.9 million during Q4 2023, and registered a low of $2.3 million during Q3 2025.
  • Over the past 5 years, Novavax's median Capital Leases value was $52.4 million (recorded in 2025), while the average stood at $39.0 million.
  • Its Capital Leases has fluctuated over the past 5 years, first surged by 7902.23% in 2023, then plummeted by 9582.66% in 2025.
  • Quarter analysis of 5 years shows Novavax's Capital Leases stood at $9.2 million in 2021, then soared by 239.8% to $31.2 million in 2022, then skyrocketed by 79.02% to $55.9 million in 2023, then decreased by 3.93% to $53.7 million in 2024, then crashed by 95.78% to $2.3 million in 2025.
  • Its Capital Leases was $2.3 million in Q3 2025, compared to $52.4 million in Q2 2025 and $53.1 million in Q1 2025.